Latest Breaking News On - Limmatech bio - Page 1 : comparemela.com

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

SCHLIEREN, Switzerland, October 09, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr

United statesNew yorkCity ofUnited kingdomAlexander siebertKabeer azizZina affas besseLimmatech biologicsFranz werner haasCamilla petrycer hansenHooft van huijsduijnenLimmatech bioNovo holdingPrincipal at novo holdingsImpact fundNational overview

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidru

SCHLIEREN, Switzerland (BUSINESS WIRE) LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platfor.

United statesNew yorkCity ofUnited kingdomZina affas besseCamilla petrycer hansenKabeer azizLimmatech bioAlexander siebertHooft van huijsduijnenFranz werner haasLimmatech biologicsTrophic communicationsNovo holdingsNovo holdingNational overview

LimmaTech Biologics AG: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

LimmaTech Biologics AG: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew yorkCity ofUnited kingdomZina affas besseHooft van huijsduijnenCamilla petrycer hansenAlexander siebertFranz werner haasLimmatech bioLimmatech biologicsKabeer azizNovo holdingsTrophic communicationsNovo nordisk foundationUnited states centers for disease

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Patricia martinPaul wolfromLimmatech biologicsThomas breuerAlexander siebertLimmatech bioGlobal healthRegulatory affairs at limmatech bioTrophic communicationsGlaxosmithkline biologicalsBtech bioWellcome trustManaging directorVice presidentRegulatory affairsChief global health officer

LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth

LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Franz werner haasLimmatech biologicsLimmatech bioAlexander siebertPhilippe droUniversity of edinburghTrophic communicationsCatholic university of leuvenUniversity of saarbrueckenChief executiveChief corporate officerChief operatingWith franzChief operating officerVice president operationsChief compliance officer